Rare diseases
Investigational molecules
Locations
703 conditions with trials, the busiest first
3 898 trials across Europe, recruiting first
Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation
AustriaStudy on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer
The NetherlandsStudy on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
FinlandStudy on Hormonal Treatment with Leuprorelin Acetate for Prostate Cancer Patients at High Risk of Recurrence After Surgery
FranceStudy Comparing Rituximab with Drug Combination for Patients with Newly Diagnosed High-Risk Burkitt Lymphoma
BelgiumStudy on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors
The NetherlandsStudy on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies
GermanyStudy on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease
DenmarkStudy Comparing Rituximab with Ibrutinib to Rituximab with Chemotherapy for Older Patients with Untreated Mantle Cell Lymphoma
DenmarkStudy on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma
The NetherlandsStudy on Copanlisib and Rituximab for Patients with Marginal Zone Lymphoma Needing Treatment After Local Therapy Failure or Relapse
GermanyStudy of Patritumab Deruxtecan for Patients with Previously Treated Metastatic or Locally Advanced EGFR-Mutated Non-Small Cell Lung Cancer
BelgiumThe therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
